Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart system aims to catch dangerous blood pressure drops earlier

NCT ID NCT07309666

Diagnosis Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new intelligent diagnostic system for orthostatic hypotension (a sudden drop in blood pressure when standing up). The system continuously monitors blood pressure, brain blood flow, and heart signals to classify the condition more precisely. Researchers plan to enroll 2000 adults with Parkinson's disease, multiple system atrophy, or diabetes who may have orthostatic hypotension. The goal is to create a risk-stratification model that could improve early detection and management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intelligent diagnostic system (non-invasive monitoring of blood pressure, brain blood flow, and heart signals)
What this could lead to
If successful, this could lead to a more accurate and automated way to diagnose and classify orthostatic hypotension, potentially reducing falls and disability in elderly and at-risk patients.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The system may not prove accurate enough for widespread use, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This prospective, multicenter study aims to enroll approximately 2000 hospitalized adult patients with Parkinson's disease, multiple system atrophy, or diabetes (aged ≥50 for diabetics) who are suspected of having or are diagnosed with orthostatic hypotension (OH). Participants will be recruited from 15 high-level clinical centers in China between March 2026 and February 2029.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (≥18 years old). 2. Clinical diagnosis of Parkinson's disease (PD) OR multiple system atrophy (MSA) OR diabetes mellitus (if diabetic, must be aged ≥50 years). 3. Suspected or diagnosed with orthostatic hypotension (OH). 4. Presence of adequate acoustic temporal bone windows for Transcranial Doppler (TCD) monitoring. 5. Willing and able to provide informed consent. Exclusion Criteria: 1. Significant intracranial or extracranial arterial stenosis (≥70% confirmed by ultrasound). 2. Recent stroke or intracerebral hemorrhage (confirmed by CT/MRI). 3. Severe cardiac arrhythmias (e.g., atrial fibrillation) or severe valvular heart disease. 4. Bilateral temporal bone windows insufficient for TCD monitoring. 5. Pregnancy or lactation. 6. Inability to cooperate with the testing procedures. 7. Other systemic diseases that significantly affect cerebral blood flow regulation (e.g., severe thyroid or renal dysfunction).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Hypotension, Orthostatic multiple system atrophy orthostatic hypotension Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Orthostatic hypotension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.